Welcome to our dedicated page for Jade Biosciences SEC filings (Ticker: JBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jade Biosciences, Inc. (JBIO) SEC filings page on Stock Titan provides access to the company’s public regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biotechnology company, Jade uses filings such as Forms 8-K, 10-Q, and 10-K to report material events, financial results, and other information related to its autoimmune disease pipeline and corporate activities.
Recent Form 8-K filings describe key transactions and developments, including private placements and PIPE financings, licensing and manufacturing agreements, and corporate changes. For example, the company has reported securities purchase agreements for private placements intended to fund research and development, general corporate expenses, and working capital; a license agreement with Paragon Therapeutics for BAFF-R–targeting antibodies; and a master services agreement with Patheon Biologics LLC for development and cGMP manufacturing of JADE101 and potential future programs.
Other 8-K filings furnish press releases that summarize quarterly financial results, cash runway expectations based on current operating plans, and updates on the clinical and preclinical status of JADE101, JADE201, and an additional undisclosed antibody program. Filings also document corporate events such as executive appointments or departures and the completion of a business combination that resulted in the current Jade Biosciences, Inc. entity and name.
Through this page, users can follow Jade’s periodic and current reports to understand how the company describes its financial condition, capital structure, material agreements, and risk factors over time. Stock Titan enhances access to these documents with AI-powered summaries that help explain the significance of filings, highlight key terms in agreements, and clarify how financing and licensing arrangements relate to the development of JADE101, JADE201, and the broader autoimmune pipeline.
Jade Biosciences Chief Financial Officer Bradford D. Dahms received new equity awards on February 12, 2026. He was granted 37,813 shares of common stock in the form of restricted stock units at no cash cost, each representing a right to one share.
These RSUs vest in four equal installments on each of the first four anniversaries of February 15, 2026, contingent on continued service. Dahms was also granted stock options for 226,875 shares of common stock with a $14.81 exercise price, granted at no cost.
One quarter of the options vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, also subject to his continued service. All reported holdings are shown as directly owned.
Jade Biosciences, Inc. granted equity awards to Chief Legal Officer and Corporate Secretary Elizabeth Balta. On February 12, 2026, she received 28,125 shares of common stock in the form of restricted stock units at $0 per share and a stock option for 168,750 shares with a $14.81 exercise price.
The RSUs vest in four equal parts on each of the first four anniversaries of February 15, 2026, if she remains in service. The option vests 25% on February 15, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, also contingent on continued service.
Frohlich Tom reported acquisition or exercise transactions in a Form 4 filing for JBIO. The filing lists transactions totaling 551,250 shares. Following the reported transactions, holdings were 472,500 shares.
Jade Biosciences, Inc. officer Andrew James King reported equity compensation awards that increase his stake in the company. On February 12, 2026, he received 41,250 shares of common stock as a grant priced at $0 per share, bringing his directly owned common shares to 386,113.
He was also granted a stock option for 247,500 shares at an exercise price of $14.81 per share, expiring on February 11, 2036, with 247,500 derivative securities owned after the grant. The 41,250-share common stock grant is in the form of restricted stock units, vesting in four equal annual installments starting on February 15, 2026. The option vests 25% on February 15, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, all subject to his continued service.
Deep Track Capital and related investors now report no beneficial ownership of Jade Biosciences, Inc. common stock. As of the event date of December 31, 2025, Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin each report 0 shares beneficially owned, representing 0.00% of the common stock.
The ownership calculations use 46,004,205 common shares outstanding as of November 7, 2025, as disclosed in Jade Biosciences’ prior quarterly report. The filing confirms that the securities referenced were not acquired or held for the purpose of changing or influencing control of Jade Biosciences.
The Vanguard Group filed an amended Schedule 13G reporting passive ownership of Jade Biosciences Inc common stock. Vanguard reports beneficial ownership of 2,095,767 shares, representing 4.24% of the outstanding common stock as of 12/31/2025.
Vanguard has shared voting power over 170,125 shares and shared dispositive power over 2,095,767 shares, with no sole voting or dispositive power. The filing notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries or business divisions are expected to report beneficial ownership separately while continuing the same investment strategies.
Jade Biosciences, Inc. entered into a securities purchase agreement for a private placement of 3,214,286 shares of common stock at $14.00 per share, for expected gross proceeds of approximately $45 million before expenses. The closing is expected on December 16, 2025, subject to customary closing conditions and in accordance with applicable Nasdaq rules.
The company plans to use the net proceeds to fund research and development, as well as general corporate expenses and working capital needs, supporting ongoing operations and pipeline development.
Jade also entered into a Registration Rights Agreement with the purchaser, committing to file a registration statement (or amend an existing one) to register the resale of the shares within 45 days after closing and to seek effectiveness within 75 days, with specified penalties if these timelines are not met. The private placement relies on exemptions from registration under Section 4(a)(2) and/or Rule 506 of Regulation D, with the investor represented as an accredited investor or qualified institutional buyer and the securities sold without general solicitation.
Jade Biosciences (JBIO)$25.2 million, driven by research and development of $22.0 million and general and administrative of $5.4 million. Interest income was $2.3 million.
Liquidity strengthened: cash and cash equivalents were $50.1 million and investments were $148.8 million, totaling $198.9 million as of September 30, 2025. The company states these resources, combined with approximately $135 million of recent financing, are expected to fund at least 12 months of operations. Year-to-date operating cash use was $61.0 million. Capital actions included conversion of $129.2 million in convertible notes into equity and a pre-closing financing, with 7,375,394 pre-funded warrants outstanding at quarter-end. Shares outstanding were 46,004,205 as of November 7, 2025.
Jade Biosciences, Inc. (JBIO) furnished its Q3 2025 results via a press release, providing an update for the quarter ended September 30, 2025. The materials were furnished, not filed, under Item 2.02.
The company also highlighted prior transaction mechanics: Aerovate completed its merger sequence with Jade on April 28, 2025, and effected a 1-for-35 reverse stock split. Historical audited financials of Pre‑Merger Jade were retroactively adjusted to the 0.6311 exchange ratio and are included as Exhibit 99.2, alongside the Q3 press release (Exhibit 99.1) and an auditor consent.